Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting

Similar Items

• Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system
  by: Raschi, Emanuel, et al.
  Published: (2015)
• Improving Pediatric Adverse Drug Event Reporting through Clinical Pharmacy Services
  by: Crowther, David M., et al.
  Published: (2011)
• Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting
  by: Ali, Ayad K, et al.
  Published: (2012)
• Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System
  by: Raschi, Emanuel, et al.
  Published: (2019)
• Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
  by: Raschi, Emanuel, et al.
  Published: (2021)